NextFin News - The venture capital landscape in India is undergoing a fundamental shift as two of its most influential backers, Accel and Prosus, have bypassed the traditional consumer-tech playbook to bet on "off-the-map" science. On Tuesday, the firms announced the selection of six startups for their inaugural joint India Atoms cohort, signaling a pivot toward deep-tech sectors including space exploration, longevity, and brain-computer interfaces. These companies, selected from a pool of over 2,000 applicants, represent a departure from the high-velocity, metric-driven investments that defined the previous decade of Indian venture capital.
The cohort includes EtherealX, a Bengaluru-based firm developing reusable orbital launch vehicles, and QOSMIC, which is building optical satellite communication systems. Beyond the stars, the selection leans heavily into biological and environmental frontiers. Praan is tackling air infrastructure, while Dognosis uses canine olfaction paired with AI to detect cancer from human breath. Ferra focuses on longevity through automated strength training, and a final startup remains in stealth, working on direct brain-to-machine communication. Each will receive checks ranging from $500,000 to $2 million, but the real innovation lies in the deal structure itself.
To accommodate the long development cycles inherent in deep tech, Accel and Prosus are utilizing a deferred equity model. This structure reduces early-stage dilution for founders, acknowledging that technical breakthroughs do not follow the linear growth curves of SaaS or e-commerce. Pratik Agarwal, a partner at Accel, noted that these founders require time more than just capital to achieve the necessary scientific milestones. This approach addresses a chronic pain point in the Indian ecosystem: the "valley of death" where capital-intensive startups perish before reaching commercial viability.
The partnership between Accel and Prosus is a calculated response to the maturing Indian market. While the country has minted dozens of unicorns in fintech and delivery, the next frontier of value creation is increasingly seen in intellectual property and hard engineering. By matching Accel’s investment, Prosus is doubling down on the thesis that India can produce global-standard hardware and biotech. This is evidenced by EtherealX’s recent $20.5 million Series A, which already valued the company at over $80 million before this cohort was even finalized.
This shift also reflects a broader geopolitical reality. As U.S. President Trump’s administration continues to emphasize technological sovereignty and supply chain resilience, Indian deep-tech firms are positioning themselves as critical partners in the global "China Plus One" strategy. Space and AI-driven healthcare are no longer just speculative bets; they are strategic assets. The success of this cohort will likely determine whether the Indian venture industry can move beyond being a "copy-paste" economy of Western business models into a genuine hub of original scientific innovation.
The risk remains high. Unlike software, where a pivot can happen in weeks, a failed rocket launch or a flawed clinical trial can wipe out years of work and millions in capital. Ashutosh Sharma, head of the India ecosystem at Prosus, admitted that progress in these fields is often binary rather than incremental. However, the sheer volume of applications—2,000 for just six spots—suggests that the talent pool in India is ready to take those risks, even if the path to a liquidity event remains years, if not a decade, away.
Explore more exclusive insights at nextfin.ai.
